Ultrasonic-assisted extraction and digestion of proteins from solid biopsies followed by peptide sequential extraction hyphenated to MALDI-based profiling holds the promise of distinguishing renal oncocytoma from chromophobe renal cell carcinoma.

Ultrasonic-assisted extraction and digestion of proteins from solid biopsies followed by peptide sequential extraction hyphenated to MALDI-based profiling holds the promise of distinguishing renal oncocytoma from chromophobe renal cell carcinoma. Talanta. 2020 Jan 01;206:120180 Authors: Jorge S, Pereira K, López-Fernández H, LaFramboise W, Dhir R, Fernández-Lodeiro J, Lodeiro C, Santos HM, Capelo-Martínez JL Abstract A novel analytical approach is proposed to discriminate between solid biopsies of chromophobe renal cell carcinoma (chRCC) and renal oncocytoma (RO). The method comprises the following steps: (i) ultrasonic extraction of proteins from solid biopsies, (ii) protein depletion with acetonitrile, (iii) ultrasonic assisted in-solution digestion using magnetic nanoparticle with immobilized trypsin, (iv) C18 tip-based preconcentration of peptides, (v) sequential extraction of the peptides with ACN, (vi) MALDI-snapshot of the extracts and (vii) investigation of the extract containing the most discriminating features using high resolution mass spectrometry. With this approach we have been able to differentially cluster renal oncocytoma and chromophobe renal cell carcinoma and identified 18 proteins specific to chromophobe and seven unique to renal oncocytoma. Chromophobes express proteins associated with ATP function (ATP5I &5E; VATE1 &G2; ADT2), glycolysis (PGK1) and neuromedin whilst oncocytomas express ATP5H, ATP...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research

Related Links:

Abstract Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma as single agent or in combination. In addition, lenvatinib has shown promise in several other tumor types including medullary, anaplastic thyroid, adenoid cystic, and endometrial cancer. Exploring synergy between angiogenic and immune checkpoint inhibitors, the lenvatinib/pembrolizumab combination is poised to become the next pair of active drugs...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Studies have identified that the polymorphism rs10069690 of telomerase reverse transcriptase (TERT) is associated with cancer risk, but the results remain inconclusive. We performed a meta ‐analysis of 45 published studies including 329,035 cases and 730,940 controls. This meta‐analysis suggested that the TERT rs10069690 polymorphism may be a risk factor for cancer, especially breast cancer, ovarian cancer, and lung cancer. Further functional studies are warranted to reveal the ro le of the polymorphism in carcinogenesis. AbstractBackgroundStudies have identified that the telomerase reverse transcriptase (TERT) gene po...
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported. A 33-year-old male on sorafenib for papillary thyroid cancer presented for evaluation of “boils” that began when he initiated chemotherapy 5 years prior and had continued to progress.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Abstract Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focus...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
ConclusionsPET/CT, as a non-invasive method, can be preferred as the first choice in the detection of primary tumor in patients with BMUO.ResumenObjetivoEste trabajo analiza el papel de la PET/TC con 18F-FDG en la detección del tumor primario en pacientes con metástasis óseas de origen desconocido (MOOD).Material y MétodosEste estudio retrospectivo consideró al análisis histopatológico o el seguimiento clínico como datos de referencia en el diagnóstico de tumores primarios y estos resultados fueron comparados con los resultados de la PET/TC.ResultadosSe incluye...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
We present two cases of nodulocystic lesions associated with comedones in patients treated with sorafenib for hepatocellular carcinoma. In the first patient, a 64-year-old man, lesions appeared on the trunk one year after beginning sorafenib. Histopathological examination revealed a non-granulomatous, perivascular and perisudoral polymorphic cellular infiltrate associated with comedones and microcysts. These lesions progressed via inflammatory episodes interrupted by long periods of spontaneous remission without any specific treatment. In the second patient, a 53-year-old woman, a rash appeared on the buttocks three months...
Source: Annales de Dermatologie et de Cenereologie - Category: Dermatology Authors: Tags: Ann Dermatol Venereol Source Type: research
Authors: Zhang C, Li H, Wang J, Zhang J, Hou X Abstract Malignant melanoma (MM) is the most aggressive form of skin cancer originating from melanocytes with increased proliferative and metastatic ability. Previous studies have revealed that microRNA-338-3p (miR-338-3p) functions as a tumor suppressor in several types of cancer, including cervical cancer, renal cell carcinoma and thyroid cancer. However, the function and mechanism underlying the action of miR-383-3p in MM remain unclear. In the study, aberrant downregulation of miR-338-3p was observed in 60 pairs of MM and adjacent non-tumor tissue using quantitativ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSIONIn the setting of a known malignancy, a nerve root metastasis should be considered in the differential diagnosis of a nerve root mass, although it occurs very rarely.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionRCC is one of the most aggressive malignancies. A high index of suspension is crucial to detect its metastasis. As some lesions maybe missed because they lack the classical radiological findings or are found in atypical locations, in addition to the latent recurrence of RCC metastasis, a lifelong follow-up is recommended.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
289Purpose: Recent development of quinoline based positron-emission-tomography (PET)-tracers that act as fibroblast-activation-protein inhibitors (FAPI) demonstrated promising preclinical and clinical results. FAP is overexpressed from cancer associated fibroblasts (CAFs) of several tumor entities. Here we quantify the tumor-uptake in FAPI-PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: FAPI-PET/CTs were requested by various clinical referees according to individual clinical indication which were considered insufficiently covered by FDG-PET/CT. All...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors (Diagnosis) Source Type: research
More News: Brain | Cancer & Oncology | Carcinoma | Chemistry | Kidney Cancer | Nanotechnology | Neurology | Renal Cell Carcinoma | Thyroid | Thyroid Cancer